Pre-Operative Tumour Marker Levels in Patients with Breast Cancer and Their Prognosis

Dalen, A. van

doi:10.1159/000217654

Cited by 12 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our hands preoperative tumor marker levels in breast cancer patients staging I or II were not related to prognosis [ 11 ]. In compar ison with CEA and CA 15-3, TPS shows a comparable number of patients with levels above the cutoff of patients with benign breast tumors, i.e., 6.9% in stage I and 10% in stage II (table 3).…”

Section: Discussionmentioning

confidence: 47%

TPS in Breast Cancer – A Comparative Study with Carcinoembryonic Antigen and CA 15-3

Dalen¹

1992

Tumor Biol

Self Cite

View full text Add to dashboard Cite

The serum levels of tissue polypeptide antigen were determined using the M3 monoclonal antibody (TPS) and compared with the serum levels of carcinoembryonic antigen (CEA) and breast carcinoma antigen 15–3 (CA 15–3) in 96 patients with benign breast tumors, in 25 breast cancer patients with no evidence of disease, in 139 preoperative breast cancer patients and in 298 samples of 25 breast cancer patients during therapy monitoring (4–22 samples per patient). The 95th percentile of TPS in 89 apparently healthy females was 51 U/l. The 95th percentile of TPS in patients with benign breast tumors was 55 U/l. The maximum TPS level in breast cancer patients with no evidence of disease was 56 U/l. In preoperative breast cancer the number of patients with TPS levels above the 95th percentile of TPS in benign breast tumors was significantly higher in stage III breast cancer as compared with stage I + II. This was not established for CEA and CA 15–3. During therapy monitoring TPS followed the course of the disease faster than CEA and CA 15–3 in patients with bone metastases, liver metastases, lung metas-tases and pleural effusion, with one exception. TPS levels could be correlated with progression of disease in patients with normal and steady levels of CEA and/or CA 15–3.

show abstract

Section: Discussionmentioning

confidence: 47%

TPS in Breast Cancer – A Comparative Study with Carcinoembryonic Antigen and CA 15-3

Dalen¹

1992

Tumor Biol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The TPS marker is a specific M3 epitope of the tissue polypeptide antigen 32, 40. The high sensitivity and usefulness in disease monitoring of TPS previously was reported in patients with breast and cervical carcinomas 46–48…”

Section: Discussionmentioning

confidence: 99%

Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma

Nagler

Barak²,

Peled

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND Mucosal oral squamous cell carcinoma (SCC) accounts for 3–5% of all reported cancers, with a 5‐year survival rate of approximately 50%. Unfortunately, current detection means are of no value in diagnosing lesions early enough for cure, especially when they recur after resection. Postoperative radiotherapy and/or covering the resection site with reconstructive flaps (regional or free vascularized) often makes early diagnosis an impossible task. METHODS The authors examined the detection and treatment monitoring capacity of two relatively new tumor markers in the serum of SCC patients, comparing their levels with those in patients with other oral/perioral malignancies or benign oral tumors and with disease free, posttreatment SCC patients and healthy controls. RESULTS Values of sensitivity, specificity, and positive and negative prediction for Cyfra 21‐1 were 96%, 87%, 93%, and 53%, respectively, whereas those for tissue polypeptide specific antigen (TPS) were 69%, 87%, 93%, and 54%, respectively. Approximately 2–3 weeks after resection of the SCC lesion, Cyfra 21‐1 and TPS levels were reduced by 47% (P ≤ 0.003) and 36% (P ≤ 0.041), respectively. Cyfra 21‐1 levels in SCC patients were significantly greater than those of healthy patients by 73% (P ≤ 0.0001), patients with benign tumors by 74% (P ≤ 0.0003), and patients in disease remission by 66% (P ≤ 0.0002). Similarly, the TPS levels of SCC patients were significantly greater than those of healthy patients by 59% (P ≤ 0.0005), patients with benign tumors by 55% (P ≤ 0.0001), and patients in disease remission by 59% (P ≤ 0.0001). In two patients, a second, new SCC lesion was diagnosed within the follow‐up period, with increased tumor markers noted concomitantly with the diagnosis. CONCLUSIONS The accumulated data point to the suitability of the clinical usage of these two markers, especially Cyfra 21‐1, in the early detection of oral SCC lesions (primary, recurrent, or secondary) as well as for treatment monitoring. These results may open new avenues for the diagnosis and follow‐up of these patients and hopefully improve their treatment outcome. Cancer 1999;85:1018–25. © 1999 American Cancer Society.

show abstract

“…[29][30][31][32][33]. Among these, the two best-established serum biomarkers for breast cancer are carbohydrate antigen 15-3 (CA 15-3) and carcinoembryonic antigen (4,34).…”

Section: Discussionmentioning

confidence: 99%

Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis

Yi¹,

Chang

Han

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

We sought to identify a new serum biomarker for breast cancer screening and diagnosis using stepwise proteomic analysis of sera from breast cancer patients to detect the presence of autoantibodies that react with urinary protein. Two-dimensional immunoblotting was done for screening autoimmunogenic tumor antigens in the urine of breast cancer patients. Reactive spots were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Among urinary proteins separated by twodimensional electrophoresis, 13 spots showed strong reactivity with pooled sera from breast cancer patients or control sera. By mass spectrometry, we identified A 2-HS glycoprotein (AHSG) as a tumor antigen. Peripheral blood was obtained from 81 women diagnosed with breast cancer before surgery and 73 female donors without evidence of any malignancy for the individual analysis. In onedimensional Western blot analysis, AHSG autoantibody was detected in 64 of 81 breast cancer patients (79.1%) and in 7 of 73 controls (9.6%). The sensitivity of this test in breast cancer patients was 79.0%. Our results suggest that AHSG and anti-AHSG autoantibody may be useful serum biomarkers for breast cancer screening and diagnosis. (Cancer Epidemiol

show abstract

Pre-Operative Tumour Marker Levels in Patients with Breast Cancer and Their Prognosis

Cited by 12 publications

References 8 publications

TPS in Breast Cancer – A Comparative Study with Carcinoembryonic Antigen and CA 15-3

TPS in Breast Cancer – A Comparative Study with Carcinoembryonic Antigen and CA 15-3

Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma

Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis

Contact Info

Product

Resources

About

Pre-Operative Tumour Marker Levels in Patients with Breast Cancer and Their Prognosis

Cited by 12 publications

References 8 publications

TPS in Breast Cancer &ndash; A Comparative Study with Carcinoembryonic Antigen and CA 15-3

TPS in Breast Cancer &ndash; A Comparative Study with Carcinoembryonic Antigen and CA 15-3

Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma

Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis

Contact Info

Product

Resources

About

TPS in Breast Cancer – A Comparative Study with Carcinoembryonic Antigen and CA 15-3

TPS in Breast Cancer – A Comparative Study with Carcinoembryonic Antigen and CA 15-3